The Aderma® Dermal Pads are proven effective pressure ulcer prevention devices available in a range of shapes and sizes to suit every patient’s needs.
Acceptance on a trust’s formulary indicates which medicines are approved to be used within hospitals and prescribed within community markets under a particular contract. The criteria to being accepted is based on evaluations of efficacy, safety, and cost-effectiveness all of which Aderma® strives to achieve.
CEO Dr Craig Barson comments on the acquisition of the Nottinghamshire Wound Care Formulary:
“We are elated with the news regarding the Nottinghamshire Wound Care Formulary.
It is always an honour to hear the Aderma® range has been accepted onto a formulary, and the fact that in this case it is the only pressure ulcer prevention device to be made available, makes it even more memorable.
Formularies are made up of approved medicines and devices making the best of the best more available in the market place. We believe Aderma® to be among the best and are credited with the fact we can now help to protect at risk patients more easily within the East Midlands area.”
For more information on Aderma® please visit the dedicated website where a host of information, including support material, can be sourced: www.aderma.info